What is the current price and trading status of PRFN.SW stock?

PRFN.SW stock trades at **CHF 0.0362** in pre-market on 22 Jan 2026, down **8.12%**, with volume **2,937,350**. It is active on the SIX exchange and showing high relative volume versus its **859,130** average.

What does Meyka AI forecast for PRFN.SW stock?

Meyka AI's forecast model projects **CHF 0.0580** for PRFN.SW in 12 months, an implied upside of **60.22%**. The model also flags a downside case to **CHF 0.0200**. Forecasts are model-based projections and not guarantees.

What are the main risks for investors in PRFN.SW stock?

Primary risks for PRFN.SW stock include clinical trial setbacks, potential dilution from capital raises, and low liquidity creating sharp price swings. Monitor company updates and trading volume closely before increasing positions.

How does PRFN.SW stock compare with its sector?

PRFN.SW is classified within Industrials for our dataset. The Industrials sector shows modest YTD strength of **+1.93%**, while PRFN.SW is materially weaker and below its 50- and 200-day averages, indicating company-specific pressure.

CH Stocks

PRFN.SW Kinarus Therapeutics SIX pre-market 22 Jan 2026: CHF 0.0362, high volume

ByDanny Kontos January 22, 2026January 22, 2026

Kinarus Therapeutics Holding AG (PRFN.SW) trades at CHF 0.0362, down 8.12%, in pre-market activity on SIX on 22 Jan 2026. The stock is among the most active issues this session with 2,937,350 shares traded versus an average of 859,130, giving a relative volume of 3.42. Investors are watching clinical progress for KIN001 and short-term liquidity signals after the price dipped below the 50-day average of CHF 0.07275. This update uses market data and Meyka AI-powered analysis to frame risks, valuation, and a model forecast for PRFN.SW stock